Eucrates Biomedical Acquisition Corp.

EUCRNASDAQFinancial Services

$10.04

+$0.00(+0.00%)

Market Cap$42228842

P/E Ratio—

52W High$10.25

52W Low$9.87

Avg Volume2K

Open$10.04

Beta-0.07

Earnings Financials Revenue

Eucrates Biomedical Acquisition Corp. (EUCR) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

EUCR · earnings · updated Jun 9, 2026

Latest Earnings

Q4 FY2022Report Date: Dec 31, 2022

EPS Actual

$0.18

Revenue

—

Fiscal Period

Q4 FY2022

FY ends December

Report Date

Dec 31, 2022

After Market Close

EUCR reports quarterly as a NASDAQ-listed Shell Companies company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

$0.35

Rev. $8.07B

Days Away84

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.$0.35

Rev. Est.$8.07B

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
— Q4 FY2022	Dec 31, 2022	—	$0.18	—	—	—	—
— Q3 FY2022	Sep 30, 2022	—	$0.09	—	—	—	—
— Q2 FY2022	Jun 30, 2022	—	$0.07	—	—	—	—
— Q1 FY2022	Mar 31, 2022	—	$0.21	—	—	—	—
— Q4 FY2021	Dec 31, 2021	—	$0.21	—	—	—	—
— Q3 FY2021	Sep 30, 2021	—	$0.07	—	—	—	—
— Q2 FY2021	Jun 30, 2021	—	$0.05	—	—	—	—
— Q1 FY2021	Mar 31, 2021	—	$0.15	—	—	—	—

Q4 FY2022

Dec 31, 2022

EPS Actual

$0.18

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q3 FY2022

Sep 30, 2022

EPS Actual

$0.09

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2022

Jun 30, 2022

EPS Actual

$0.07

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2022

Mar 31, 2022

EPS Actual

$0.21

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2021

Dec 31, 2021

EPS Actual

$0.21

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q3 FY2021

Sep 30, 2021

EPS Actual

$0.07

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2021

Jun 30, 2021

EPS Actual

$0.05

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2021

Mar 31, 2021

EPS Actual

$0.15

EPS Est.

—

EPS Surpr.

—

Revenue

—

No analyst estimates available for EUCR.

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
— Q4 FY2022	Dec 31, 2022	—	$9.99	$9.99	+0.00%
— Q3 FY2022	Sep 30, 2022	—	$10.03	$10.02	-0.10%
— Q2 FY2022	Jun 30, 2022	—	$9.90	$9.90	+0.00%
— Q1 FY2022	Mar 31, 2022	—	$9.84	$9.84	+0.00%
— Q4 FY2021	Dec 31, 2021	—	$9.82	$9.76	-0.61%
— Q3 FY2021	Sep 30, 2021	—	$9.75	$9.78	+0.31%
— Q2 FY2021	Jun 30, 2021	—	$9.89	$9.85	-0.46%
— Q1 FY2021	Mar 31, 2021	—	$9.92	$9.98	+0.60%

Q4 FY2022+0.00%

Report Date

Dec 31, 2022

EPS Beat/Miss

—

Price Before

$9.99

Price After

$9.99

Q3 FY2022-0.10%

Report Date

Sep 30, 2022

EPS Beat/Miss

—

Price Before

$10.03

Price After

$10.02

Q2 FY2022+0.00%

Report Date

Jun 30, 2022

EPS Beat/Miss

—

Price Before

$9.90

Price After

$9.90

Q1 FY2022+0.00%

Report Date

Mar 31, 2022

EPS Beat/Miss

—

Price Before

$9.84

Price After

$9.84

Q4 FY2021-0.61%

Report Date

Dec 31, 2021

EPS Beat/Miss

—

Price Before

$9.82

Price After

$9.76

Q3 FY2021+0.31%

Report Date

Sep 30, 2021

EPS Beat/Miss

—

Price Before

$9.75

Price After

$9.78

Q2 FY2021-0.46%

Report Date

Jun 30, 2021

EPS Beat/Miss

—

Price Before

$9.89

Price After

$9.85

Q1 FY2021+0.60%

Report Date

Mar 31, 2021

EPS Beat/Miss

—

Price Before

$9.92

Price After

$9.98

Beat Rate0 / 8 quarters

Largest Move-0.61% (Q4 FY2021)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Eucrates Biomedical Acquisition Corp. (EUCR) most recently reported earnings on December 31, 2022 for Q4 FY2022, posting EPS of $0.18 (in line with the analyst consensus of —). The next EUCR earnings date is expected around September 1, 2026.

Each quarter, investors track EUCR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EUCR revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

EUCR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

EUCR earnings · 4 questions

Eucrates Biomedical Acquisition Corp.'s next earnings report is expected around September 1, 2026. EUCR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EUCR historically reports after market close (AMC).

EUCR earnings datewhen is EUCR earningsEUCR next earnings datewhen does EUCR report earningsEUCR earnings calendar

▸ Source: FMP · Eucrates Biomedical Acquisition Corp. SEC filings · US GAAP · Eucrates Biomedical Acquisition Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026